Cepheid Expects to Report Q3 Revenues Below Target | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Wednesday that it expects to report third-quarter revenues of between $79 million and $81 million, below its own target range and Wall Street's average estimate of $83.8 million.

The Sunnyvale, Calif.-based firm said the shortfall is due to "intermittent interruptions in the supply of Xpert cartridge parts." The Xpert cartridges contain the tests that run on the firm's GeneXpert systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.